Leadership 2

Brian Wong, MD, PhD

Dr. Wong joined The Column Group in 2022 as a Venture Partner. He is CEO of RAPT Therapeutics. Prior to RAPT, he served as Senior Vice President, Research, and Head of Immuno-Oncology at Five Prime Therapeutics. Prior to FivePrime, Dr. Wong served as Director in the Inflammation Disease Biology Area at Roche. There, he led […]

Brian Wong, MD, PhD Read More »

Hui Tian, PhD

Dr. Hui Tian joined The Column Group in 2022 as a Venture Partner.  Previously he was a founding member of NGM Biopharmaceuticals and most recently served as Senior Vice President of Research.  In this role, he was responsible for discovery research across multiple therapeutic areas including metabolic diseases, retinal diseases and cancer.  In a span

Hui Tian, PhD Read More »

Jeff Goater

Jeff Goater joined The Column Group as a Venture Partner in 2021. Previously, he served as Chief Executive Officer of Surface Oncology.  During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. 

Jeff Goater Read More »

Sarah Hymowitz, PhD

Dr. Hymowitz joined The Column Group in 2021.  Previously, she spent 22 years at Genentech rising to Vice President of Protein Sciences. In this role, she oversaw the large molecule drug discovery portfolio and mentored project teams on the identification and optimization of more than 35 clinical candidates. Earlier, as a member of the Genentech

Sarah Hymowitz, PhD Read More »

Millie Ray, PhD

Millie Ray, PhD

Dr. Ray joined The Column Group in 2017. Previously, Dr. Ray was an Associate of Business Development at Foghorn Therapeutics, which she helped launch with Flagship Pioneering. Dr. Ray helped develop and execute the scientific, business and operating plans for Foghorn Therapeutics. Dr. Ray helped establish the first onsite next-generation sequencers for Ebola viral surveillance

Millie Ray, PhD Read More »

James Evangelista

James Evangelista

Mr. Evangelista joined The Column Group in 2012 and has almost two decades of venture capital industry experience. Previously, he was with Three Arch Partners, and prior to that, Lightspeed Venture Partners. He began his career working for several large money management firms including Fisher Investments and Barclays Global Investors. Mr. Evangelista is a Certified

James Evangelista Read More »

John Josey

John Josey, PhD

Dr. Josey joined The Column Group as a Venture Partner in 2020. Previously he served as the President, Chief Executive Officer and a member of the Board of Directors of Peloton Therapeutics, Inc., from 2013 until its acquisition by Merck in 2019. He joined Peloton in 2011 as the first employee in the role of

John Josey, PhD Read More »

Leon Chen, PhD

Dr. Chen joined The Column Group in 2019. Previously, he was a Venture Partner at OrbiMed focusing on company creation and investing in early stage biotech companies. In this capacity he took on interim management roles at E-Scape Bio, TranscripTx and Adicet. He also served on the board of Pionyr Immunotherapeutics and Logic Bio. Prior

Leon Chen, PhD Read More »

Larry Lasky, PhD

Larry Lasky, PhD

Dr. Lasky joined The Column Group in 2014. He has worked in the biotechnology industry for over 30 years. In 1981, he was a founding scientist of Genetics Institute, acquired by Wyeth, one of the earliest biotechnology companies. He was subsequently a leading scientist at Genentech and eventually a Genentech Fellow. He worked in various

Larry Lasky, PhD Read More »

Scroll to Top